



# VALUE & INNOVATION in MULTIPLE MYELOMA



5-year relative survival rates for multiple myeloma from 1990-2014 increased more than four times faster than for other cancers.<sup>1</sup>



## Advances in Myeloma Treatments Continue to Improve the Relative Survival Rates for Patients<sup>2</sup>



In 2018, Celgene is supporting **206** global investigator-led trials and cooperative groups in multiple myeloma.<sup>3</sup>



**4 of the 5** novel agents launched in multiple myeloma since 2013 have been approved for use in combination with a Celgene therapy.<sup>4</sup>

1. National Cancer Institute, SEER Cancer Statistics Review 1975-2015. Difference in 5-year relative survival between the 1990-1992 cohort and the 2007-2014 cohort calculated. Data on file at Celgene.  
 2. Drawid A et al. Impact of Novel Therapies on Multiple Myeloma - Current and Future Outcomes. Poster presented at the 20th Congress of the European Haematology Association; Vienna, Austria, June 11-14, 2015.  
 3. Internal data on investigator-led trials and COOPs.  
 4. U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. Retrieved from: <http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm>.